scholarly journals Monoclonal IgG anticoagulants delaying fibrin aggregation in two patients with systemic lupus erythematosus (SLE)

Blood ◽  
1978 ◽  
Vol 52 (5) ◽  
pp. 1037-1046
Author(s):  
DK Galanakis ◽  
EM Ginzler ◽  
SM Fikrig
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Self Assembly ◽  
Anticoagulant Activity ◽  
Rabbit Serum ◽  
Distinct Region ◽  
Thrombin Time ◽  
Systemic Lupus ◽  
Fibrinogen Molecule ◽  
Anticoagulant Property

There is paucity of information regarding the prolonged plasma thrombin time known to occur in some patients with systemic lupus erythematosus. Detailed investigations of plasma from two such patients disclosed that IgG accounted for this defect in each case. IgG isolated from plasma of either patient possessed the property of delaying fibrin aggregation and prolonging the clotting times of fibrinogen. Preincubation of IgG from either patient with anti-IgG or anti-Fab (rabbit) serum abolished this anticoagulant property. Moreover, the anticoagulant IgG from the first patient was neutralized with anit-k chain and anti-IgG3, that from the second patient with anti-lambda chain and anti-IgG1 serum. These anticoagulants were also dissimilar with respect to their interactions with fibrin(ogen). IgG from the first patient had no anticoagulant activity against fibrin(ogen) species lacking intact Aalpha chains. IgG from the second patient displayed undiminished anticoagulant effect on such fibrin(ogen) species. We conclude that each anticoagulant interacted with a distinct region(s) on the fibrinogen molecule and that these interactions affect or involve sites that participate in the fibrin self-assembly process.

scholarly journals Monoclonal IgG anticoagulants delaying fibrin aggregation in two patients with systemic lupus erythematosus (SLE)

Blood ◽  
1978 ◽  
Vol 52 (5) ◽  
pp. 1037-1046 ◽  
Author(s):  
DK Galanakis ◽  
EM Ginzler ◽  
SM Fikrig
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Self Assembly ◽  
Anticoagulant Activity ◽  
Rabbit Serum ◽  
Distinct Region ◽  
Thrombin Time ◽  
Systemic Lupus ◽  
Fibrinogen Molecule ◽  
Anticoagulant Property

Abstract There is paucity of information regarding the prolonged plasma thrombin time known to occur in some patients with systemic lupus erythematosus. Detailed investigations of plasma from two such patients disclosed that IgG accounted for this defect in each case. IgG isolated from plasma of either patient possessed the property of delaying fibrin aggregation and prolonging the clotting times of fibrinogen. Preincubation of IgG from either patient with anti-IgG or anti-Fab (rabbit) serum abolished this anticoagulant property. Moreover, the anticoagulant IgG from the first patient was neutralized with anit-k chain and anti-IgG3, that from the second patient with anti-lambda chain and anti-IgG1 serum. These anticoagulants were also dissimilar with respect to their interactions with fibrin(ogen). IgG from the first patient had no anticoagulant activity against fibrin(ogen) species lacking intact Aalpha chains. IgG from the second patient displayed undiminished anticoagulant effect on such fibrin(ogen) species. We conclude that each anticoagulant interacted with a distinct region(s) on the fibrinogen molecule and that these interactions affect or involve sites that participate in the fibrin self-assembly process.

The Coagulation Abnormalities in Systemic Lupus Erythematosus

1968 ◽  
Vol 20 (03/04) ◽  
pp. 457-464 ◽  
Author(s):  
L Gonyea ◽  
R Herdman ◽  
R. A Bridges
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Ammonium Sulfate ◽  
Lupus Erythematosus ◽  
Anticoagulant Activity ◽  
Species Specificity ◽  
Sensitive Assay ◽  
Systemic Lupus ◽  
Coagulation Abnormalities

SummaryAn anticoagulant occurring in 4 of 6 patients with SLE has been demonstrated by a sensitive assay utilizing an ammonium sulfate fraction of serum. The anticoagulant functions as an inhibitor of the activation of prothrombin. No species specificity was demonstrable. The inhibitor behaves clinically and chromatographically as an immunoglobulin, although an attempt to demonstrate directly the antibody nature of the inhibitor was not successful.A severe, apparently independent, decrease in the level of prothrombin was observed in the patient with hemorrhagic symptoms. In contrast to the anticoagulant activity, the low prothrombin has persisted during treatment.

scholarly journals A Plasma Coagulation Defect in Systemic Lupus Erythematosus Arising from Hypoprothrombinemia Combined with Antiprothrombinase Activity

Blood ◽  
1960 ◽  
Vol 15 (2) ◽  
pp. 212-227 ◽  
Author(s):  
SAMUEL I. RAPAPORT ◽  
SARA BETH AMES ◽  
BARBARA J. DUVALL
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Anticoagulant Activity ◽  
The Other ◽  
Severe Bleeding ◽  
Systemic Lupus ◽  
Plasma Coagulation ◽  
Complex Plasma ◽  
Coagulation Defect

Abstract A patient has been described with systemic lupus erythematosus and severe bleeding. Her bleeding was associated with a complex plasma coagulation disturbance consisting of profound hypoprothrombinemia plus an anticoagulant active against formed blood and tissue prothrombinase. The problem of the recognition of hypoprothrombinemia in the presence of this type of anticoagulant has been discussed in detail. An analysis of previously reported cases reveals that our patient’s findings are not unique. It appears that the plasma coagulation disturbances of systemic lupus erythematosus characteristically result from a mixture of anticoagulant activity and true hypoprothrombinemia. In an individual patient one or the other may predominate.

Inhibition of Lupus Anticoagulant Activity by Hexagonal Phase Phosphatidylethanolamine in the Presence of Prothrombin

1998 ◽  
Vol 80 (12) ◽  
pp. 936-941 ◽  
Author(s):  
Marion Tannenbaum ◽  
Carolyn Neville ◽  
Paul Fortin ◽  
Joyce Rauch
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Lupus Anticoagulant ◽  
Plasma Proteins ◽  
Anticoagulant Activity ◽  
Hexagonal Phase ◽  
Annexin V ◽  
Systemic Lupus ◽  
Glycoprotein I ◽  
No Inhibition

SummaryWe have previously demonstrated that lupus anticoagulant antibodies from patients with systemic lupus erythematosus (SLE) specifically recognize hexagonal (II) phase phosphatidylethanolamine (PE), but not bilayer PE (Thromb Haemost 1989; 62: 892). In those studies, the involvement of proteins in this recognition was not evaluated. To address this issue, we have isolated IgG lupus anticoagulant antibodies from the plasma of SLE patients and evaluated the inhibition of lupus anticoagulant activity by hexagonal (II) phase PE in the presence and absence of purified plasma proteins. All six of the IgG lupus anticoagulant antibodies tested were inhibited by hexagonal (II) phase PE in the presence, but not the absence, of human prothrombin. In contrast, little or no inhibition was observed with prothrombin alone or with PE in combination with either β2-glycoprotein I or annexin V. These data indicate that, for certain lupus anticoagulant antibodies, inhibition by hexagonal (II) phase PE is dependent on prothrombin, suggesting that these antibodies recognize a complex of PE and prothrombin.

Prevalence of Annexin A5 Resistance in Children and Adolescents with Rheumatic Diseases

2011 ◽  
Vol 39 (2) ◽  
pp. 382-388 ◽  
Author(s):  
DAWN M. WAHEZI ◽  
NORMAN T. ILOWITE ◽  
SWAPNIL RAJPATHAK ◽  
JACOB H. RAND
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Connective Tissue ◽  
Children And Adolescents ◽  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
Antiphospholipid Antibodies ◽  
Anticoagulant Activity ◽  
Underlying Mechanism ◽  
Annexin A5 ◽  
Systemic Lupus

Objective.The underlying mechanism(s) by which antiphospholipid antibodies (aPL) result in thrombosis remains poorly understood. A significant body of evidence has evolved to support the hypothesis that antibody-mediated disruption of an annexin A5 anticoagulant shield may play a role in the pathogenesis; this proposed mechanism has not been previously studied in children.Methods.We investigated the association between aPL and resistance to annexin A5 anticoagulant activity in 90 children with a variety of rheumatic diseases using a novel mechanistic assay, the annexin A5 resistance assay (A5R).Results.Patients with a diagnosis of primary aPL syndrome, systemic lupus erythematosus, and mixed connective tissue disease demonstrated lower mean A5R levels (p = 0.030), higher prevalence of positive aPL (p < 0.001), and more thrombotic events (p = 0.014) compared to those with other diagnoses. Patients with persistently positive aPL had significantly lower mean A5R compared to patients with no aPL (mean A5R = 203% ± 44% vs 247% ± 35%; p < 0.001), whereas patients with transient aPL did not. Patients with thrombosis had lower A5R levels compared to those without thrombosis (mean A5R = 207% ± 36% vs 237% ± 46%; p = 0.048).Conclusion.Children and adolescents with rheumatic diseases and persistent aPL have reduced annexin A5 anticoagulant activity, whereas transient, nonpathogenic aPL have less effect on annexin A5 activity.

Hemocoagulation in patients with systemic lupus erythematosus under pulse therapy

2018 ◽  
Author(s):  
Н.П. Шилкина ◽  
И.В. Масина ◽  
А.В. Замышляев
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Protein C ◽  
Vascular Wall ◽  
Pulse Therapy ◽  
Thrombin Time ◽  
Systemic Lupus ◽  
Central Nervous System Damage ◽  
At Iii ◽  
High Doses

Введение. Ревматические заболевания относятся к процессам, характеризующимся иммунным поражением различных органов и систем с выраженными изменениями сосудистой стенки и системы гемостаза. Цель исследования: изучить влияние высоких доз глюкокортикостероидов (ГКС) и цитостатиков на клинико-гемостазиологические показатели у больных системной красной волчанкой (СКВ). Материалы и методы. Обследовано 18 больных СКВ женщин (средний возраст — 35,6 ± 1,6 года), которые получали пульс-терапию ГКС и цитостатиком циклофосфаном по стандартной схеме. Критерии отбора для проведения пульс-терапии: высокая активность аутоиммунного процесса по шкалам SLAM, SLEDAI, ECLAM, поражение почек и центральной нервной системы. Гемостазиологические показатели исследовали до лечения, на 1-й и 14-й день после пульс-терапии. Для оценки состояния коагуляционного звена гемостаза определяли: активированное частичное тромбопластиновое время, тромбиновое время, протромбиновое время по Квику, содержание фибриногена, растворимых фибрин-мономерных комплексов, Д-димера, активность антитромбина III (АТ-III), протеина С, фибринолитической системы крови. Результаты. У больных СКВ наблюдали активацию коагуляционного гемостаза на фоне снижения активности естественных антикоагулянтов и процессов фибринолиза. На 1-е сутки после пульс-терапии выявлен значительный рост тромбинемии; к 14-у дню большинство показателей плазменного гемостаза возвращались к исходным на фоне снижения активности системы протеина С и роста активности АТ-III. Заключение. Исследование коагулологических параметров следует проводить всем больным СКВ, получающим пульс-терапию, так как существует угроза развития тромбозов у данных пациентов. Полученные данные подтверждают необходимость применения антикоагулянтов при назначении высоких доз ГКС и цитостатиков. Introduction. Rheumatic diseases are characterized by the immune damage of various organs and systems with expressed changes in the vascular wall and hemostasis. Aim: to study the eff ect of high doses of glucocorticosteroids (GCS) and cytostatics on the clinical and hemostasiological parameters in patients with systemic lupus erythematosus (SLE). Materials and methods. We examined 18 women with SLE of (average age — 35.6 ± 1.6 years) who received pulse therapy by GCS and cyclophosphamide according to the standard scheme. Selection criteria for pulse therapy were high activity of the autoimmune process according to SLAM, SLEDAI, ECLAM scales, kidney and central nervous system damage. Hemostasiological parameters were investigated before treatment, on the 1st and 14th days after pulse therapy. To assess the state of coagulation hemostasis, we determined: activated partial thromboplastin time, thrombin time, Quick prothrombin time, fibrinogen content, soluble fi brin-monomer complexes, D-dimer, activity of antithrombin III (AT-III), protein C, fibrinolytic system. Results. In patients with SLE, activation of coagulation hemostasis was observed with the reduction in the activity of natural anticoagulants and fi brinolysis processes. On the 1st day after pulse therapy, a signifi cant thrombinemia growth was detected; by the 14th day, most of plasma hemostatic parameters returned to baseline with reduction of protein C system activity and increasing of AT-III activity. Conclusion. The study of coagulological parameters should be carried out in all patients with SLE who receive pulse therapy, since there is a risk of thrombosis in these patients. The obtained data confirm the need for anticoagulants use in the appointment of high doses of GCS and cytostatics.

Sign in / Sign up

Export Citation Format

Share Document